Meeting
2022 ASCO Annual Meeting
Clinical implications for patients with discordant oncotype and MammaPrint results.
Authors
Matei P. Socoteanu
Texas Oncology-Longview Cancer Center, US Oncology, Longview, TX
Matei P. Socoteanu , Joyce O'Shaughnessy , Kent Hoskins , Adam Brufsky , Cathy Lynne Graham , Svetislava J. Vukelja , Jamal Ghazi Misleh , Karen L. Tedesco , Rakhshanda Layeequr Rahman , June Lee , Julian Berrocal , Kamal Sharma , Albert Begas , Jennifer Crozier , Ian Grady , Nina D'Abreo , Midas M. Kuilman , Holly Nguyen , Lisa Eileen Blumencranz , M. William Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT03053193
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 560)
DOI
10.1200/JCO.2022.40.16_suppl.560
Abstract #
560
Poster Bd #
332
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
First Author: Jose Antonio Lopez Guerrero
Poster
2016 ASCO Annual Meeting
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
First Author: Oleg Gluz
Poster
2015 ASCO Annual Meeting
Evaluation of the Breast Cancer Index in patients with HER2+/HR+ breast cancer for risk of late recurrence and potential extended endocrine benefit.
First Author: Ruth O'Regan
Poster
2011 ASCO Annual Meeting
Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence.
First Author: D. F. Bajorin